EUCTR2006-000314-20-DE进行中（未招募）不适用
A randomized placebo-controlled clinical trial of topical photodynamic therapy with a nanoemulsion formulation of 5-aminolevulinic acid for the treatment of actinic keratosis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Are willing and able to sign informed consent form.
- •2. Men and women aged between 18 and 85 years.
- •3. Accept to abstain from sunbathing and the solarium during the study.
- •4. Have at least 3 clinically confirmed AK target lesions within the face or scalp (excluding eylids, lips and mucosa). The AK lesions must be discrete and quantifiable. The total AK lesion area should not exceed 200 cm2.
- •5. Are free of any significant physical abnormalities (eg, tattoos, dermatoses) in the potential treatment area that may cause difficulty with examination or final evaluation.
- •6. Are willing to stop using moisturizers and any other topical treatments with anti-aging products, vitamin A, vitamin C, and/or vitamin E containing ointments and creams, and green tea preparations during the study within the treatment area. Sunscreens will be allowed, but should not be applied in the treatment area within approximately 24 hours of a clinic visit with lesion count.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have known hypersensitivity to ALA.
- •2. Have received any other medication known to affect AK 3 months before or during the study.
- •3. Are patients under immunosuppression therapy.
- •4. Suffer from porphyria.
- •5. Show hypersensitivity to porphyrins.
- •6. Suffer from photodermatoses.
- •7. Have inherited or acquired coagulation defects.
- •8. Receive medication with hypericin or any photosensitizer.
- •9. Have evidence of clinically significant, unstable medical conditions such as metastatic tumor or tumor with high probability of metastatic spread, cardiovascular (NYHA class III, IV), immunosuppressive, hematologic, hepatic, renal, neurologic, endocrine, collagen-vascular, gastrointestinal disease
- •10. Have currently other malignant or benign tumors of the skin within the treatment area (e.g., malignant melanoma, basal cell carcinoma, squamous cell carcinoma).
- •11./12. Have received treatments as listed for any indication in the treatment area or systemic treatments as listed within the designated time period before PDT treatment with ALA
- •13. Treatment with ALA.
- •14. Known allergy against polysorbate 80, capylic/capric acid triglycerides, isopropyl alcohol, disodium phosphate dihydrate, sodium hydroxide, hydrochloric acid, propylene glycol, methyl parahydrobenzoate, or propyl parahydrobenzoate; compare with Section 7.1).
- •15. Are known to be pregnant or lactating (currently or within the past 3 months).
- •16. Have any dermatological disease in the treatment area or surrounding area that may be exacerbated by treatment with topical ALA or cause difficulty with examination (e.g. psoriasis, eczema).
研究者
相似试验
已完成
不适用
A randomized placebo controlled clinical trial of a rehabilitation programme for patients with a diagnosis of massive, irreparable rotator cuff tears of the shoulderISRCTN64734872Record Provided by the NHSTCT Register - 2006 Update - Department of Health60
尚未招募
3 期
A placebo-controlled, randomized clinical trial of vigabatrin in the management of acute alcohol withdrawalalcohol withdrawalMental Health - AddictionACTRN12607000362493Professor Jon Currie120
尚未招募
2 期
A placebo-controlled, randomized clinical trial of Bioeffective A in the management of acute alcohol withdrawal and alcohol abstinence maintenancealcohol dependenceACTRN12609000649213Professor Jon Currie56
尚未招募
2 期
Clinical study on the effect of Navayas Lauha (an ayurvedic classical formulation) and specific diet in the management of obesity(sthaulya)CTRI/2024/02/062731G J Patel Institute of Ayurvedic Studies and Research
进行中（未招募）
1 期
A study testing whether the cholesterol-lowering medicine fenofibrate can slow down the progression of diabetic eye diseaseEUCTR2016-002656-24-GBniversity of Oxford (Clinical Trials and Research Governance))1,060